Navigation Links
Osteotech Receives 13485:2003 ISO Certification; Company Meets International Standards for Medical Device Manufacturing
Date:2/19/2009

EATONTOWN, N.J., Feb. 19 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic products for regenerative healing, announced today that it has received ISO 13485:2003 certification for its quality management system. Osteotech received ISO certification for developing, manufacturing and marketing of biologic, biomaterial and device systems for musculoskeletal surgery and the processing of human bone and connective tissue for transplantation. Osteotech's wholly-owned subsidiaries, OST Developpement SA and TB OsteoCentre Bulgaria EAD previously received ISO 9001 certification, and OST also previously received ISO 13485:2003 certification, for their quality management systems.

"We are very pleased to announce that we have received ISO certification for our U.S. quality management system," said Sam Owusu-Akyaw, President and Chief Executive Officer of Osteotech. "The certification reinforces our commitment to maintaining a high quality processing facility and to ensuring the safety of those patients that utilize our products. Receiving the certification is an important milestone as we continue towards our goal to become a leader in regenerative and biologic healing."

Osteotech's facilities in Eatontown, New Jersey and Clermont-Ferrand, France are the processing sites for the Company's allograft tissue grafts utilized in its broad portfolio of therapy-driven products focused on promoting regenerative and biologic healing. To date, Osteotech has successfully processed more than four million tissue grafts worldwide. The Company's advanced technology platforms, all processed at its Eatontown facility, include Grafton(R) DBM and the Plexur(R) Biocomposite family of products as well as the DuraTech(TM) BioRegeneration Matrix, Osteotech's leading product based upon its proprietary human collagen technology platform. Osteotech recently initiated a pivotal clinical trial to evaluate the safety of the DuraTech BioRegeneration Matrix for dura mater repair during craniotomy procedures. During the third and fourth quarters of 2009, the Company intends to file regulatory applications with the United States Food and Drug Administration and with the competent authority in certain other countries to obtain marketing clearance for DuraTech BioRegeneration Matrix.

"ISO certification validates the quality systems we have put in place to ensure the integrity of all of our products," added Greg Cannedy, Vice President of Regulatory Affairs at Osteotech. "Certification of our U.S. facilities complements the ISO certifications received by our European subsidiaries and marks an important step forward in bringing future products, including our DuraTech BioRegeneration Matrix, to market."

About ISO Certification

The International Organization for Standardization ("ISO") is a world-wide federation of national standards bodies. ISO certification is an international standard that specifies a quality management system for the development, production and distribution of medical devices and related services.

About Osteotech

Osteotech, Inc., headquartered in Eatontown, New Jersey, is a global leader in providing OsteoBiologic solutions for regenerative medicine to support surgeons and their patients through the development of innovative therapy-driven products that alleviate pain, promote regenerative and biologic healing and restore function. For further information regarding Osteotech or this press release, please go to Osteotech's website at http://www.osteotech.com.

Certain statements made throughout this press release that are not historical facts contain forward-looking statements (as such are defined in the Private Securities Litigation Reform Act of 1995) regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the Company's ability to develop and introduce new products, differences in anticipated and actual product and service introduction dates, the ultimate success of those products in the marketplace, the continued acceptance and growth of current products and services, the impact of competitive products and services, the availability of sufficient quantities of suitable donated tissue and the success of cost control and margin improvement efforts. These and other factors that could cause actual results to differ materially from such forward-looking statements are detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. All information in this press release is as of February 19, 2009 and the Company does not intend to update this information.


'/>"/>
SOURCE Osteotech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Osteotech to Present at First Albany Capitals Regenerative Technologies Conference in New York
2. Osteotech Completes Tissue Supply Agreement With LifeNet Health
3. Osteotech Announces Third Quarter Earnings Release and Conference Call Schedule
4. Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09
5. Osteotech Signs Agreement To Distribute Harvest Technologies BMAC(TM) System
6. Osteotech Engages BioHorizons as Exclusive Distributor to International Dental Market
7. Osteotech Announces the Unexpected Passing of Audit Committee Member Leads to Receipt of Nasdaq Deficiency Letter
8. Osteotech Reports 2008 Second Quarter Diluted Earnings Per Share of $.10 on Revenues of $27.6 Million
9. Osteotech Expands Senior Management Team; New Executives to Drive Sales Force Strategies and Therapy-Based Solutions
10. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
11. DaVita Receives Civil Complaint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 23, 2017 , ... The January 2017 issue of the ... study on how outdoor behavioral healthcare (OBH) – also known as wilderness therapy – ... while experiencing an increased sense of purpose both during and after treatment. , ...
(Date:1/24/2017)... ... January 23, 2017 , ... ... a new plugin that allows sleep centers to automatically connect and initialize all ... a thin client browser plugin is quickly installed on first use and then ...
(Date:1/23/2017)... Alto, CA (PRWEB) , ... ... ... a provider of translation and localization services for life science companies, has ... and inspection organization, TÜV SÜD America. ISO 17100 is the globally recognized ...
(Date:1/23/2017)... ... 23, 2017 , ... Wooden and plastic balance boards have been around since at least the ... Board is the first and only balance board to use a patent-pending design featuring ... at the same time as well as skill-level adjustable for all ages and abilities. ...
(Date:1/23/2017)... Indiana (PRWEB) , ... January 23, 2017 , ... ... Center for Assisted Living (IHCA/INCAL), will serve as a healthcare industry expert at ... 23. The panel discussion, moderated by Inside Indiana Business host Gerry Dick, will ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... Stock-Callers.com today presents the following Generic ... CPRX ), Sophiris Bio Inc. (NASDAQ: SPHS ), ... Therapeutics Inc. (NASDAQ: AGRX ). These companies are ... late trade on Friday, January 20 th , 2017, with ... of health care companies in the S&P 500 also were ...
(Date:1/23/2017)... , January 23, 2017 The global  anxiety disorders and ... by 2025. The rising incidence of depression worldwide is anticipated to drive the ... resulted in the declining demand for antidepressants in the recent years. ... ... Grand View Research Logo ...
(Date:1/23/2017)... DIEGO and PALMA, Spain ... Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company ... that the first patient has been enrolled in ... lead candidate, SNF472, for the treatment of cardiovascular ... (HD). Most ESRD patients, in the ...
Breaking Medicine Technology: